Immutep Ltd (IMM)

0.250
0.000(0.00%)
  • Volume:
    379,512
  • Bid/Ask:
    0.250/0.255
  • Day's Range:
    0.245 - 0.255
Trading near 52-week Low

Immutep has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

IMM Overview

Prev. Close
0.25
Day's Range
0.245-0.255
Revenue
2.3M
Open
0.255
52 wk Range
0.245-0.71
EPS
-0.038
Volume
379,512
Market Cap
216.56M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
863,501
P/E Ratio
-7.51
Beta
1.93
1-Year Change
-54.21%
Shares Outstanding
866,239,815
Next Earnings Date
Nov 30, 2022
What is your sentiment on Immutep?
or
Market is currently closed. Voting is open during market hours.

Immutep Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Immutep Ltd Analysis

Immutep Ltd Company Profile

Immutep Ltd Company Profile

Employees
0
Market
Australia

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.

Read More

Analyst Price Target

Average117.800 (+47020.00% Upside)
High200
Low65
Price0.25
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsBuyStrong BuySellStrong SellStrong Sell
SummaryNeutralNeutralSellStrong SellStrong Sell